Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP30341 (Molnupiravir) in Healthy Volunteers and High-Risk COVID-19 Patients
NCT05648799Phase 2Completed
- Sponsor
- Geropharm
- Start
- Mar 2022
- Primary completion
- May 2022
- Modality
- RNA-Targeting Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of molnupiravir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Geropharm. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration up to 36 hours, Maximum Plasma Concentration up to 36 hours and 3 more. Started Mar 2022; status: completed.
02
Drugs
molnupiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05648799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05648799.